J. O’Gorman

发表

Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.

M. Freedman, S. Lo, J. Zeng, 2001, Journal of the National Cancer Institute.

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2016, Nature.

Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia.

E. Barrett-Connor, L. Mosca, D. Cox, 2001, Clinical therapeutics.

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.

A. Menter, K. Gordon, J. O’Gorman, 2003, Archives of dermatology.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2017, Nature.

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

Nikolaus R. McFarland, S. Haeberlein, M. Grossman, 2019, The Lancet Neurology.

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

S. Haeberlein, P. Chiao, A. Sandrock, 2017, The journal of prevention of Alzheimer's disease.

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

S. Haeberlein, A. Lang, M. Grundman, 2021, Nature Medicine.

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

J. Sevigny, J. O’Gorman, Alvydas Mikulskis, 2016, Alzheimer's & dementia.

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

K. Dawson, R. Fox, R. Scannevin, 2014, Current medical research and opinion.

The Personal Suicide Stigma Questionnaire (PSSQ): Relation to Self-Esteem, Well-Being, and Help-Seeking

J. O’Gorman, Jacinta Hawgood, Jurgita Rimkevičienė, 2023, International journal of environmental research and public health.

Chronic hormone replacement therapy alters thermoregulatory and vasomotor function in postmenopausal women.

J. Derr, A. Morgan, J. O’Gorman, 1997, Journal of applied physiology.

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.

G. Phillips, J. O’Gorman, V. Viglietta, 2015, Clinical therapeutics.

Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004)

S. Haeberlein, R. Nitsch, C. Hock, 2018 .

CHRONIC HORMONE REPLACEMENT THERAPY ALTERS THERMOREGULATORY AND VASOMOTOR FUNCTION IN POSTMENOPAUSAL WOMEN 1080

A. Morgan, J. O’Gorman, J. Pierzga, 1997 .

Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease: Interim results of a randomized, double-blind, placebo-controlled, phase 1b study

Roger M. Nitsch, Leslie Williams, Ping Chiao, 2015, Alzheimer's & Dementia.

Construct Validity of the Acquired Capability for Suicide Scale: Factor Structure, Convergent and Discriminant Validity

D. de Leo, J. O’Gorman, Jacinta Hawgood, 2016, Journal of Psychopathology and Behavioral Assessment.

Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.

I. Nestorov, S. Sheikh, K. Dawson, 2013, Clinical therapeutics.

Development of a cognitive composite for measuring change in progressive supranuclear palsy.

S. Haeberlein, J. O’Gorman, J. Jaeger, 2021, Parkinsonism & related disorders.

Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab

Brian Avants, Alex P. Zijdenbos, Robert Koeppe, 2019, The Journal of Nuclear Medicine.

Baseline characteristics from TANGO: Phase 2 study to evaluate gosuranemab (BIIB092) in patients with early Alzheimer’s disease

D. Walsh, L. Viollet, J. O’Gorman, 2020, Alzheimer's & Dementia.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

M. Hutchinson, E. Havrdová, K. Dawson, 2013, Journal of Neurology.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study

D. Arnold, L. Kappos, A. Bar-Or, 2013, Journal of Neurology.

Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

Viglietta, D. Miller, M. Hutchinson, 2012 .

Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130)

D. Arnold, L. Kappos, A. Bar-Or, 2012 .

Safety, Tolerability, and Pharmacokinetics of BG-12 Administered with and without Aspirin: Key Findings from a Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Volunteers (P04.136)

I. Nestorov, S. Sheikh, K. Dawson, 2012 .

The Role of Impulsivity and Self-Control in Suicidal Ideation and Suicide Attempt

J. O’Gorman, Jacinta Hawgood, Aleena Martin, 2023, International journal of environmental research and public health.

Enzyme potentiated hyposensitization: IV. effect of protamine on the immunological behavior of beta glucuronidase in mice and patients with hay fever.

J. O’Gorman, I. Kitchen, L. Mcewen, 1975, Annals of allergy.

Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003)

F. Barkhof, M. Sano, S. Salloway, 2016 .

TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease

S. Haeberlein, J. O’Gorman, J. Czerkowicz, 2023, Nature aging.

Results from the long‐term extension of PRIME: A randomized Phase 1b trial of aducanumab

S. Haeberlein, R. Nitsch, J. O’Gorman, 2024, Alzheimer's & dementia : the journal of the Alzheimer's Association.